Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Delcath Systems stock

Own Delcath Systems stock in just a few minutes.

Delcath Systems, Inc is a medical devices business based in the US. Delcath Systems shares (DCTH) are listed on the NASDAQ and all prices are listed in US Dollars. Delcath Systems employs 36 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Delcath Systems

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DCTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Delcath Systems share price

Use our graph to track the performance of DCTH stocks over time.

Delcath Systems shares at a glance

Information last updated 2021-04-29.
52-week range$7.15 - $25.18
50-day moving average $15.01
200-day moving average $15.78
Wall St. target price$22.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Delcath Systems shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Delcath Systems stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Delcath Systems financials

Revenue TTM $1.6 million
Gross profit TTM $1 million
Return on assets TTM -54.52%
Return on equity TTM -307.31%
Profit margin 0%
Book value $3.68
Market capitalisation $73.8 million

TTM: trailing 12 months

Shorting Delcath Systems shares

There are currently 361,047 Delcath Systems shares held short by investors – that's known as Delcath Systems's "short interest". This figure is 13.5% down from 417,446 last month.

There are a few different ways that this level of interest in shorting Delcath Systems shares can be evaluated.

Delcath Systems's "short interest ratio" (SIR)

Delcath Systems's "short interest ratio" (SIR) is the quantity of Delcath Systems shares currently shorted divided by the average quantity of Delcath Systems shares traded daily (recently around 564135.9375). Delcath Systems's SIR currently stands at 0.64. In other words for every 100,000 Delcath Systems shares traded daily on the market, roughly 640 shares are currently held short.

However Delcath Systems's short interest can also be evaluated against the total number of Delcath Systems shares, or, against the total number of tradable Delcath Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Delcath Systems's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Delcath Systems shares in existence, roughly 60 shares are currently held short) or 0.0585% of the tradable shares (for every 100,000 tradable Delcath Systems shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Delcath Systems.

Find out more about how you can short Delcath Systems stock.

Delcath Systems share dividends

We're not expecting Delcath Systems to pay a dividend over the next 12 months.

Have Delcath Systems's shares ever split?

Delcath Systems's shares were split on a 1:700 basis on 23 December 2019. So if you had owned 700 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Delcath Systems shares – just the quantity. However, indirectly, the new 69900% higher share price could have impacted the market appetite for Delcath Systems shares which in turn could have impacted Delcath Systems's share price.

Delcath Systems share price volatility

Over the last 12 months, Delcath Systems's shares have ranged in value from as little as $7.15 up to $25.18. A popular way to gauge a stock's volatility is its "beta".

DCTH.US volatility(beta: 0.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Delcath Systems's is 0.583. This would suggest that Delcath Systems's shares are less volatile than average (for this exchange).

Delcath Systems overview

Delcath Systems, Inc. , an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site